Compare ORRF & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORRF | ZVRA |
|---|---|---|
| Founded | 1919 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.5M | 741.9M |
| IPO Year | 1995 | 2015 |
| Metric | ORRF | ZVRA |
|---|---|---|
| Price | $39.70 | $12.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $42.00 | $23.00 |
| AVG Volume (30 Days) | 120.2K | ★ 2.1M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 182.43 | 159.21 |
| EPS | ★ 1.12 | 0.60 |
| Revenue | $37,144,000.00 | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | $3.15 | $53.42 |
| P/E Ratio | $34.90 | ★ $21.08 |
| Revenue Growth | 36.00 | ★ 350.91 |
| 52 Week Low | $31.51 | $7.16 |
| 52 Week High | $40.72 | $14.27 |
| Indicator | ORRF | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 60.90 |
| Support Level | $34.95 | $8.26 |
| Resistance Level | $40.26 | $14.27 |
| Average True Range (ATR) | 1.19 | 0.75 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 85.91 | 65.13 |
Orrstown Financial Services Inc is a financial holding company. Through its subsidiaries, it operates in the community banking segment and engages in lending activities, including commercial, residential, commercial mortgages, construction, municipal, and various forms of consumer lending and deposit services, including checking, savings, time, and money market deposits. The Group also provides fiduciary, investment advisory, insurance, and brokerage services. It offers services to individuals, professionals, small businesses, and other enterprises across different locations in the United States through its branch network and client service centers.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.